scPharmaceuticals (NASDAQ:SCPH) Given New $12.00 Price Target at Maxim Group

scPharmaceuticals (NASDAQ:SCPH) had its target price cut by Maxim Group from $20.00 to $12.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research note on Thursday.

scPharmaceuticals Trading Down 0.3 %

SCPH opened at $3.00 on Thursday. scPharmaceuticals has a 12 month low of $2.75 and a 12 month high of $5.65. The stock has a market capitalization of $150.12 million, a price-to-earnings ratio of -1.58 and a beta of 0.40. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The business has a fifty day moving average price of $3.27 and a 200 day moving average price of $3.78.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The company had revenue of $12.15 million during the quarter, compared to the consensus estimate of $12.08 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. Sell-side analysts expect that scPharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On scPharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in SCPH. Suvretta Capital Management LLC acquired a new position in scPharmaceuticals during the 3rd quarter worth approximately $9,343,000. Rubric Capital Management LP increased its position in scPharmaceuticals by 35.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after purchasing an additional 1,250,000 shares during the period. King Luther Capital Management Corp increased its position in scPharmaceuticals by 28.4% during the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock worth $10,117,000 after purchasing an additional 632,120 shares during the period. Rice Hall James & Associates LLC increased its position in scPharmaceuticals by 59.2% during the 4th quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock worth $3,503,000 after purchasing an additional 367,970 shares during the period. Finally, Stonepine Capital Management LLC increased its position in scPharmaceuticals by 84.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after purchasing an additional 357,171 shares during the period. Institutional investors and hedge funds own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.